Long-term effect of donepezil for Alzheimer's disease: Retrospective clinical evaluation of drug efficacy in Japanese patients

Psychogeriatrics

Volumn 8, Issue 1, 2008, Pages 19-23

  Kumagai, Ryo ^a   Matsumiya, Michiko ^a   Tada, Yuko ^a   Miyakawa, Koichi ^a   Ichimiya, Yosuke ^a   Arai, Heii ^a  

^a JUNTENDO TOKYO KOTO GERIATRIC MEDICAL CENTER   (Japan)

Author keywords

Alzheimer's disease; Dementia; Donepezil; Japanese patient; Long term effect

Indexed keywords

APOLIPOPROTEIN E; DONEPEZIL;

AGED; AGGRESSION; ALZHEIMER DISEASE; ANAMNESIS; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; COGNITION; COMPARATIVE STUDY; CONTROLLED STUDY; DELIRIUM; DISEASE SEVERITY; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL DISEASE; GENDER; HUMAN; JAPAN; JAPANESE; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RHABDOMYOLYSIS; SIDE EFFECT; TREATMENT DURATION; UNIVERSITY HOSPITAL; UNSPECIFIED SIDE EFFECT;

EID: 40349084397     PISSN: 13463500     EISSN: 14798301     Source Type: Journal    
DOI: 10.1111/j.1479-8301.2007.00217.x     Document Type: Article

References (19)

1. Matsushita M. What is Alzheimer's disease? Brain Sci 2000; 22: 13-18 (in Japanese).
2. Jorm AF, Jolley D. The incidence of dementia: A meta-analysis. Neurology 1998; 51: 728-733.
3. Watanuki Y, Urakami K, Adachi Y et al. Epidemiology in Alzheimer type dementia. Brain Sci 2000; 22: 21-26 (in Japanese).
4. Nakamura S. A guideline for the treatment of dementia in Japan. Intern Med 2004; 43: 18-29.
5. Tohgi H, Homma A, Imai Y et al. Long-term safety and efficacy of acetylcholinesterase inhibitor E2020 in patients with Alzheimer-type dementia: 52-week open label study. Rinsho Hyoka 2000; 28: 97-126 (in Japanese).
6. Kono K. Clinical evaluation of donepezil, the 1st report: Over 3 months of donepezil treatment improved 51% of 221 patients with either Alzheimer's disease or Pick's disease. Rinsho Seisin Yakuri 2000; 3: 1053-1060 (in Japanese).
7. O'Brien J, Ames D, Burns A. Dementia, 2nd edn. London: Arnold, 2000.
8. Imai Y, Hasegawa K. The revised Hasegawa's dementia scale (HDS-R): Evaluation of its usefulness as a screening test for dementia. J Hong Kong Coll Psychiatry 1994; 4: 20-24.
9. Rogers SL, Doody RS, Pratt RD et al. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: Final analysis of a US multicentre open-label study. Eur Neuropsychopharmacol 2000; 10: 195-203.
10. Rogers SL, Friedhoff LT. Long-term efficacy and safety of donepezil in the treatment of Alzheimer's disease: An interim analysis of the results of a US multicentre open label extension study. Eur Neuropsychopharmacol 1997; 31: 67-75.
11. AD 2000 Collaborative Group. Long-term donepezil treatment in 565 patients with Alzheimer's disease (AD2000): Randomized double-blind trial. Lancet 2004; 363: 2105-2115.
12. Kivipelto M, Helkala E-L, Laakso MP et al. Midlife vascular risk factors and Alzheimer's disease in laterlife: Longitudinal, population based study. BMJ 2001; 322: 1447-1451.
13. Otto A, Stolk RP, van Harskamp F et al. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 1999; 53: 1937-1942.
14. Borroni B, Colciaghi F, Pastorino L et al. ApoE gynotype influences the biological effect of donepezil on APP metabolism in Alzheimer disease: Evidence from a peripheral model. Eur Neuropsychopharmacol 2002; 12: 195-200.
15. Bizzarro A, Marra C, Acciarri A et al. Apolipoprotain E e4 allele differentiates the clinical response to donepezil in Alzheimer's disease. Dement Geriatr Cogn Disord 2005; 20: 254-261.
16. Rigaud AS, Traykov L, Latour F et al. Presence or absence of at least one e4 allele and gender are not predictive for the response to donepezil treatment in Alzheimer's disease. Pharmacogenetics 2002; 12: 415-420.
17. Winblad B, Engedal K, Soininen H et al. A 1-year, randomized, placebo-controlled study of donepezil in patients with mild to moderate AD. Neurology 2001; 57: 489-495.
18. Rogers SL, Farlow MR, Doody RS et al. A 24-week, double-blind, placebo-controlled trial of donepezil in patients with Alzheimer's disease. Neurology 1998; 50: 136-145.
19. Burns A, Gauthier S, Perdomo C. Efficacy and safety of donepezil over 3 years: An open-label, multicentre study in patients with Alzheimer's disease. Int J Geriatr Psychiatry 2007; 22: 806-812.